The Association between Peptide Hormones with Obesity and Insulin Resistance Markers in Lean and Obese Individuals in the United Arab Emirates

The Association between Peptide Hormones with Obesity and Insulin Resistance Markers in Lean and Obese Individuals in the United Arab Emirates

Peptide hormones play a crucial role in body weight and glucose homeostasis. In this study, we aimed to explore this association and recruited 43 obese and 31 age- and sex-matched lean participants. We assessed their body mass index (BMI), waist circumference (WC), waist-to-height ratio (WtHR), perc...

Full description

Bibliographic Details
Main Authors:	Manal Ali Ahmad, Mirey Karavetian, Carole Ayoub Moubareck, Gabi Wazz, Tarek Mahdy, Koen Venema
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Nutrients
Subjects:	obesity brain–gut axis insulin resistance glucagon-like peptide-1 glucagon-like peptide-2 insulin
Online Access:	https://www.mdpi.com/2072-6643/14/6/1271

Similar Items

The Association of Peptide Hormones with Glycemia, Dyslipidemia, and Obesity in Lebanese Individuals
by: Murielle Abou-Samra, et al.
Published: (2022-11-01)

Assessing the Effect of Incretin Hormones and Other Insulin Secretagogues on Pancreatic Beta-Cell Function: Review on Mathematical Modelling Approaches
by: Giovanni Pacini, et al.
Published: (2022-05-01)

Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs
by: Anubhav Pratap-Singh, et al.
Published: (2023-09-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
by: Tina Zimmermann, et al.
Published: (2022-12-01)

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus
by: Sung Hoon Yu, et al.
Published: (2011-02-01)

Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages
by: C. Guo, et al.

Effects of GLP-1 Receptor Polymorphisms on Adolescent Obesity
by: Mahafarin Maralani, et al.
Published: (2023-07-01)

Stimulatory effect of imeglimin on incretin secretion
by: Quan Yingyue, et al.
Published: (2023-06-01)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes
by: Kozlovski P, et al.
Published: (2017-03-01)

Association of the gut microbiota with clinical variables in obese and lean Emirati subjects
by: Manal Ali Ahmad, et al.
Published: (2023-08-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2018-12-01)

Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01)

Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
by: Mi Yeon Kang, et al.
Published: (2015-06-01)

Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice
by: Chen X, et al.
Published: (2022-11-01)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
by: Vijaya Subramanian, et al.
Published: (2022-09-01)

Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
Published: (2010-09-01)

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice
by: Yangzhao Zhou, et al.
Published: (2023-09-01)

Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells
by: Yun Kyung Jeon, et al.
Published: (2014-12-01)

Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01)

Are obese rats influenced by GLP1 and IR through aerobic exercise? A case study
by: Ali Sayyah, et al.
Published: (2016-08-01)

MS-275, a class 1 histone deacetylase inhibitor augments glucagon-like peptide-1 receptor agonism to improve glycemic control and reduce obesity in diet-induced obese mice
by: Shilpak Bele, et al.
Published: (2020-12-01)

Preliminary results from digestive adaptation: a new surgical proposal for treating obesity, based on physiology and evolution
by: Sérgio Santoro, et al.

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway
by: Yang P, et al.
Published: (2019-07-01)

Liraglutide improved inflammation via mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin
by: Pin Chen, et al.
Published: (2021-10-01)

Effects of Fasting on Glucagon-like peptide-1 hormone (GLP-1), and Lipid Profile Indices in Obese and Thin Women
by: Shahrbanoo Haghighi, et al.
Published: (2019-03-01)

Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries
by: Brandon B. Boland, et al.
Published: (2022-01-01)

Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon
by: Eonju Jeon, et al.
Published: (2023-06-01)

Glycemic Control and Metabolic Adaptation in Response to High-Fat versus High-Carbohydrate Diets—Data from a Randomized Cross-Over Study in Healthy Subjects
by: Ville Wallenius, et al.
Published: (2021-09-01)

Roles of glucose‐dependent insulinotropic polypeptide in diet‐induced obesity
by: Yusuke Seino, et al.
Published: (2022-07-01)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
by: Lee J, et al.
Published: (2019-12-01)

Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin
by: Hsuan-Wen Chou, et al.
Published: (2022-12-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
by: Nina A. Petunina, et al.
Published: (2018-09-01)

Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study
by: Ondrej Krystynik, et al.
Published: (2023-01-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

Issues of insulin therapy for type 2 diabetes and ways to solve them
by: V.I. Katerenchuk, et al.
Published: (2023-05-01)

Prediction of early response to liraglutide therapy in patients with obesity
by: Oksana V. Logvinova, et al.
Published: (2020-06-01)

Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019-03-01)